PCT - An Uncontrolled Clinical Trial for Treatment of Androgen Induced Hypogonadism
نویسنده
چکیده
[70] Bartsch G, Scheiber K. Tamoxifen Treatment in Oligozoospermia. European Urology. 1981; 7(5): 283-287. and iatrogenic Cushing’s syndrome Cihak RW, Beary FD. Elevated Triiodothyronine and Dextrothyroxine Levels: A Potential Cause of Iatrogenic Hyperthyroidism. Southern Medical Journal. 1977 Feb; 70(2): 256-257. Smidt KP, Johnston E. Undetected Iatrogenic Hypothyroidism: A Late Complication of Radio-Iodine Therapy. New Zealand Medical Journal. 1975 Apr 9; 81: 325-328. Tuel SM, Meythaler JM, Cross LL. Cushing’s Syndrome from Epidural Methylprednisolone. Pain. 1990 Jan; 40(1): 81-84. Kimmerle R, Rolla AR. Iatrogenic Cushing’s Syndrome Due to Dexamethasone Nasal Drops. American Journal of Medicine. 1985 Oct; 79(4): 535-537.
منابع مشابه
A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management
Context Middle-aged and older men (≥50 years), especially those who are obese and suffer from comorbidities, not uncommonly present with clinical features consistent with androgen deficiency and modestly reduced testosterone levels. Commonly, such men do not demonstrate anatomical hypothalamic-pituitary-testicular axis pathology but have functional hypogonadism that is potentially reversible. ...
متن کاملOsteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism.
BACKGROUND No randomized study exists comparing the effects of different modes of androgen substitution on bone mineral density (BMD). METHODS We performed a prospective, randomized, trial assigning 53 hypogonadal men to the following treatment groups: mesterolone 100 mg p.o. daily, testosterone undecanoate 160 mg p.o. daily, testosterone enanthate 250 mg i.m. every 21 days, or a single subcu...
متن کاملSelective androgen receptor modulators for the treatment of late onset male hypogonadism
Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinetic basis of approval and dearth of long-term safety data. The brevity and relatively reduced cost of pharmacokinetic based registration trials provides little commercial incentive ...
متن کاملHypogonadism in the HIV-Infected Man
Androgen deficiency occurs frequently in men with human immunodeficiency virus (HIV) infection. Antiretroviral treatments had reduced the prevalence of male hypogonadism. The pathogenesis of testosterone (T) deficiency in HIV is multifactorial. Several mechanisms have been proposed; among them, drugs, fat redistribution, and a poor health status could explain the mechanism leading to gonadotrop...
متن کاملTransdermal testosterone replacement therapy in men
Androgen deficiency syndrome in men is a frequently diagnosed condition associated with clinical symptoms including fatigue, decreased libido, erectile dysfunction, and metabolic syndrome. Serum testosterone concentrations decline steadily with age. The prevalence of androgen deficiency syndrome in men varies depending on the age group, known and unknown comorbidities, and the respective study ...
متن کامل